Precision Health, Built Through Women's Health.
Women's biology is healthcare's untapped frontier. Fern backs clinically validated, technology-enabled companies translating deeper biological understanding into better diagnostics, prevention, treatment, and care delivery.
$0T+
economic opportunity in women's health
$0B+
global FemTech market
0%
more time spent in poor health by women globally
0%
of global private healthcare investment directed towards women's health
Across the UK–Europe–Africa corridor, we back companies with the potential to redefine routine care across diverse health systems.
Healthcare cannot be truly precise without understanding women.
Learn moreOur investment focus
STAGE FOCUS
Seed to Series A
Debut Dignity Fund I invests between $250,000 and $1m in clinically validated, technology-enabled women's health ventures.
SCALABLE SOLUTIONS
We invest in platforms that improve the prediction, diagnosis, management, and delivery of care across conditions exclusively, differently or disproportionately affecting women.
LONG-TERM VALUE CREATION
We back businesses with durable commercial models, clear pathways to growth, and the capacity to deliver sustained healthcare impact over time.
CROSS-MARKET SCALABILITY
Fern invests across the UK, Europe, Nigeria, Kenya, South Africa, and Egypt, backing companies positioned to scale across both established and high-growth healthcare systems.
Building the future of healthcare?
We're looking for founders transforming how health is understood, delivered, and adopted. If you're building solutions that improve outcomes and can scale across healthcare systems, we'd love to hear from you. Submit your pitch deck or get in touch.
